Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mannkind Corp (MNKD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 313,630
  • Shares Outstanding, K 152,990
  • Annual Sales, $ 11,750 K
  • Annual Income, $ -117,330 K
  • 36-Month Beta 2.27
  • Price/Sales 25.14
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +41.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.51 +35.76%
on 10/12/18
2.19 -6.39%
on 10/18/18
+0.32 (+18.50%)
since 09/18/18
3-Month
0.98 +109.18%
on 08/06/18
3.04 -32.57%
on 09/05/18
+0.44 (+27.33%)
since 07/18/18
52-Week
0.98 +109.18%
on 08/06/18
4.45 -53.93%
on 10/20/17
-2.08 (-50.36%)
since 10/18/17

Most Recent Stories

More News
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement

United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development...

UTHR : 125.83 (-0.92%)
MNKD : 2.05 (+6.22%)
Afrezza(R) Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity

Broadcast spot recognized at 2018 Medical Marketing & Media (MM&M) Awards

MNKD : 2.05 (+6.22%)
United Therapeutics In-Licenses Rights to IPF Candidate

United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.

PCRX : 48.21 (+0.35%)
MNKD : 2.05 (+6.22%)
UTHR : 125.83 (-0.92%)
BSTC : 61.60 (+0.82%)
Positive Afrezza(R) Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics

MannKind Corporation (Nasdaq:MNKD) announced today that "Improved Postprandial Glucose with Inhaled Technosphere(R) Insulin Compared to Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily...

MNKD : 2.05 (+6.22%)
Implied Volatility Surging for MannKind (MNKD) Stock Options

MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.

MNKD : 2.05 (+6.22%)
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals

PBYI : 43.57 (-0.68%)
VRTX : 178.90 (-3.55%)
AMGN : 202.72 (-0.02%)
MNKD : 2.05 (+6.22%)
UTHR : 125.83 (-0.92%)
MannKind Stock Up on Licensing Deal With United Therapeutics

MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

ILMN : 321.45 (-2.28%)
GILD : 74.17 (-1.92%)
MNKD : 2.05 (+6.22%)
UTHR : 125.83 (-0.92%)
Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars

Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.

PBYI : 43.57 (-0.68%)
VRTX : 178.90 (-3.55%)
AMGN : 202.72 (-0.02%)
MNKD : 2.05 (+6.22%)
UTHR : 125.83 (-0.92%)
Innovative Diagnostic Technology Playing Significant Role in Improving Detection for Better Cardiac Care

PALM BEACH, Florida, September 5, 2018 /PRNewswire/ --

ZENO : 0.3050 (unch)
BSX : 37.53 (-1.24%)
BEAT : 55.06 (-2.12%)
IRTC : 82.69 (-4.02%)
MNKD : 2.05 (+6.22%)
3 Stocks to Watch As The Healthcare Sector Heats Up

CORAL GABLES, FL / ACCESSWIRE / September 4, 2018 / Health care stocks have made a sharp swing to the upside so far in the third quarter, leading the some of the major markets like the S&P 500. Sector...

REPH : 7.18 (-0.83%)
MNKD : 2.05 (+6.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MNKD with:

Business Summary

Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder...

See More

Key Turning Points

2nd Resistance Point 2.34
1st Resistance Point 2.19
Last Price 2.05
1st Support Level 1.90
2nd Support Level 1.76

See More

52-Week High 4.45
Fibonacci 61.8% 3.12
Fibonacci 50% 2.71
Fibonacci 38.2% 2.31
Last Price 2.05
52-Week Low 0.98

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar